RIG-I is essential for radiation-induced IFN-β production and PD-L1/PD-L2 upregulation in HPV-negative head and neck squamous cell carcinoma cells
6 affiliations
- 1Translational Radiobiology, Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- 2Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- 3Comprehensive Cancer Center Erlangen-Europäische Metropolregion Nürnberg (EMN), Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- 4Bavarian Cancer Research Center (BZKF), Erlangen, Germany
- 5Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany
- 6Department of Translational Immunology, Nikolaus-Fiebiger Center of Molecular Medicine, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany
Abstract
The RIG-I pathway, a key component of the innate immune system that classically detects cytosolic viral RNA, has also been implicated in regulating tumor cell viability, radiosensitivity, and patient survival across multiple cancer types. However, these effects appear to be context-dependent and partly contradictory. Whether radiotherapy modulates tumor-intrinsic RIG-I signaling in head and neck squamous cell carcinoma (HNSCC) depending on HPV status, and whether such modulation is associated with changes in the tumor immune phenotype, remains unknown. Four human HNSCC cell lines (two HPV-negative and two HPV-positive), along with siRNA-mediated RIG-I knockdown and a CRISPR/Cas9-generated RIG-I knockout derivative, were treated with radiotherapy. Tumor cells were analyzed for their immune phenotype, including RIG-I expression via Western blot and flow cytometry, IFN-β secretion via ELISA, and PD-L1 and PD-L2 expression via flow cytometry. Radiotherapy, dose- and fraction-dependent, induced the upregulation of RIG-I expression and IFN-β secretion from HPV-negative HNSCC cells. The knockdown and knockout of the RIG-I-encoding gene DDX58 in the HPV-negative cell line HSC4 minimized both IFN-β secretion and PD-L1 and PD-L2 expression. These effects could be replicated by pre-exposing HPV-negative cell lines to the RIG-I inhibitor RIG012 before irradiation. Interestingly, HPV-positive cells showed less radiotherapy-mediated modulation of RIG-I and of the tumor cell phenotype of immune-related surface markers and showed no significant reaction to the inhibitor treatment. The previously unrecognized RIG-I-IFN-β axis is a central regulator of RT-induced immune checkpoint modulation for HPV-negative HNSCC. These results provide new opportunities to reshape the immune response following RT in HNSCC.
Related
- Stereotactic body radiation therapy enriches mediators of humoral immune activity in metastatic renal cell carcinoma.
- Negative Word Production in Bilinguals Triggers Inhibitory Mechanisms: Evidence from Mass Univariate Time-Frequency Analysis
- Alcohol Promotes ER+ Breast Cancer Cell Proliferation and Invasion Through the Upregulation of Neuregulin 1-Mediated ER-ErbB3 Crosstalk
- Pan-cancer multi-omics analysis reveals upregulation of the POLE2 subunit of DNA polymerase epsilon and its associations with patient survival and cellular pathways beyond DNA replication
- Senescence-associated KRAS upregulation in peripheral T cells links to premature coronary artery disease
BibTeX
@article{gottwald2026rigi,
title = {{RIG-I is essential for radiation-induced IFN-β production and PD-L1/PD-L2 upregulation in HPV-negative head and neck squamous cell carcinoma cells}},
author = {Anna Gottwald and Marlen Haderlein and Christina B. Brunner and Michael Rückert and Katharina Pracht and Stefanie Corradini and Benjamin Frey and Udo S. Gaipl and Tina Jost},
journal = {Oncoimmunology},
year = {2026},
month = nov,
doi = {10.1080/2162402x.2026.2757877},
url = {https://doi.org/10.1080/2162402x.2026.2757877},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - RIG-I is essential for radiation-induced IFN-β production and PD-L1/PD-L2 upregulation in HPV-negative head and neck squamous cell carcinoma cells
AU - Anna Gottwald
AU - Marlen Haderlein
AU - Christina B. Brunner
AU - Michael Rückert
AU - Katharina Pracht
AU - Stefanie Corradini
AU - Benjamin Frey
AU - Udo S. Gaipl
AU - Tina Jost
PY - 2026
DA - 2026/11/06
JO - Oncoimmunology
DO - 10.1080/2162402x.2026.2757877
UR - https://doi.org/10.1080/2162402x.2026.2757877
AB - The RIG-I pathway, a key component of the innate immune system that classically detects cytosolic viral RNA, has also been implicated in regulating tumor cell viability, radiosensitivity, and patient survival across multiple cancer types. However, these effects appear to be context-dependent and partly contradictory. Whether radiotherapy modulates tumor-intrinsic RIG-I signaling in head and neck squamous cell carcinoma (HNSCC) depending on HPV status, and whether such modulation is associated with changes in the tumor immune phenotype, remains unknown. Four human HNSCC cell lines (two HPV-negative and two HPV-positive), along with siRNA-mediated RIG-I knockdown and a CRISPR/Cas9-generated RIG-I knockout derivative, were treated with radiotherapy. Tumor cells were analyzed for their immune phenotype, including RIG-I expression via Western blot and flow cytometry, IFN-β secretion via ELISA, and PD-L1 and PD-L2 expression via flow cytometry. Radiotherapy, dose- and fraction-dependent, induced the upregulation of RIG-I expression and IFN-β secretion from HPV-negative HNSCC cells. The knockdown and knockout of the RIG-I-encoding gene DDX58 in the HPV-negative cell line HSC4 minimized both IFN-β secretion and PD-L1 and PD-L2 expression. These effects could be replicated by pre-exposing HPV-negative cell lines to the RIG-I inhibitor RIG012 before irradiation. Interestingly, HPV-positive cells showed less radiotherapy-mediated modulation of RIG-I and of the tumor cell phenotype of immune-related surface markers and showed no significant reaction to the inhibitor treatment. The previously unrecognized RIG-I-IFN-β axis is a central regulator of RT-induced immune checkpoint modulation for HPV-negative HNSCC. These results provide new opportunities to reshape the immune response following RT in HNSCC.
SN - 2162-4011
SN - 2162-402X
ER -